Virus-specific T cells in pediatric renal transplantation

Thurid Ahlenstiel-Grunow1 · Lars Pape1

Received: 23 December 2019 / Revised: 25 February 2020 / Accepted: 25 February 2020 / Published online: 27 March 2020
© The Author(s) 2020

Abstract
After pediatric kidney transplantation, immunosuppressive therapy causes an increased risk of severe viral complications, especially from cytomegalovirus (CMV), BK polyomavirus (BKPyV) or Epstein-Barr virus (EBV), and less frequent from adenovirus (ADV). However, suitable predictive markers for the individual outcome of viral infections are missing and the therapeutic management remains a challenge to the success of pediatric kidney transplantation. Virus-specific T cells are known for controlling viral replication and there is growing evidence that virus-specific T cells may serve as a prognostic marker to identify patients at risk for viral complications. This review provides an overview of the usability of virus-specific T cells for improving diagnostic and therapeutic management of viral infections with reference to the necessity of antiviral prophylaxis, timing of pre-emptive therapy, and dosing of immunosuppressive medication after pediatric kidney transplantation. Several studies demonstrated that high levels of virus-specific T cells are associated with decrease of virus load and favorable outcome, whereas lack of virus-specific T cells coincided with virus-induced complications. Accordingly, the additional monitoring of virus-specific T cells aims to personalize the management of antiviral therapy, identify overimmunosuppression, and avoid unnecessary therapeutic interventions. Prospective randomized trials in pediatric kidney recipients comparing standard antiviral and immunosuppressive regimens with T cell-guided therapeutic interventions are needed, before monitoring of virus-specific T cells is implemented in the routine care of pediatric kidney graft recipients.

Keywords BK polyomavirus · Cytomegalovirus · Epstein-Barr virus · Adenovirus · Virus-specific T cells · Kidney transplantation · Pediatric transplantation · Immunosuppression · Viral infections · Prognostic marker

Introduction
After pediatric kidney transplantation, the immunosuppressive treatment disturbs the individual balance between virus replication and cellular immune response resulting in an elevated incidence of severe viral complications. Post-transplant primary infections or reactivations, especially by cytomegalovirus (CMV), BK polyomavirus (BKPyV) or Epstein-Barr virus (EBV), and less frequent by adenovirus (ADV), are associated with increased morbidity, mortality, and graft failure, for example, CMV disease [1], BKPyV-associated nephropathy (BKPyVAN) [2], and EBV-associated post-transplant lymphoproliferative disease (PTLD) [3]. The outcome of post-transplant viral infections is individually different, but prognostic markers are missing. Virus DNA and serology are the actual diagnostic standard to use for steering immunosuppressive and antiviral therapy in the case of primary infections or reactivations but they are insufficient to precisely predict the individual risk of viral complications. An antiviral prophylaxis or pre-emptive therapy is often recommended especially for CMV, but antiviral medication should be restricted to patients with an elevated risk of viral disease because of the high costs and severe side effects [4]. If antiviral drugs are not available, a pre-emptive reduction of immunosuppressive therapy is often performed in case of post-transplant viremia to avoid viral complications, especially for BKPyV [5] or for EBV [6], but on the other hand, it is associated with an increased risk of underimmunosuppression and rejections. Because of lack of prognostic markers, it is actually difficult to limit therapeutic interventions to patients with risk of viral complications like BKPyVAN and PTLD. Therefore, the necessity of antiviral prophylaxis, the timing of pre-emptive antiviral therapy, and the optimal dosing of immunosuppressive therapy remain a subject for debate opening a window for new
biomarkers that could help to differentiate between patients with or without a need of therapeutic intervention as antiviral medication and/or reduction of immunosuppressive therapy to prevent viral complications.

Virus-specific T cells have been shown to play a significant role in control of virus replication [7]: Virus-specific CD4-positive T cells detect viral epitopes which are presented on major histocompatibility complex (MHC) class II molecules on antigen-presenting cells such as B lymphocytes, dendritic cells and macrophages, and CD8-positive T cells locate and destroy virus-infected cells which present viral antigens by MHC class I molecules. Several studies, mainly in adults, have shown that the number of virus-specific T cells is associated with the risk of virus-specific complications [8–19]. Therefore, prophylaxis, diagnosis, and treatment of viral infections after kidney transplantation may be improved by the implementation of virus-specific T cells in routine monitoring [7]. There is increasing evidence that virus-specific T cells mirror not only the virus-specific but also the general cellular immune defense. Thus, they might be additionally used for steering of the intensity of immunosuppressive treatment to avoid overimmunosuppression [7, 20]. This review will summarize the current knowledge regarding the utility of virus-specific T cells as a diagnostic tool after pediatric kidney transplantation. Currently, there is additional knowledge on diagnostic procedures and treatment with virus-specific T cells in human stem cell transplantation. This review is limited to kidney transplantation although insights from stem cell transplantation that can be transferred to solid organ transplantation are also included in the therapy section.

Methods for detection and quantification of virus-specific T cells

A number of different assays are currently available for the detection of the cellular response to viral antigens [7], the main ones being the enzyme-linked immunosorbent (ELISpot) assay, the enzyme-linked immunospot assay (ELISA), intracellular cytokine staining followed by fluorescence-activated cell sorting (FACS) analysis, and MHC multimer staining. ELISpot, ELISA, and FACS assays are based on stimulation of virus-specific T cells followed by induction of activation markers. For stimulation, antigens such as virus-infected cell lysates, virus particles, proteins, or peptides are used. The easiest methodology is the ELISA, where cytokines such as interferon γ can be measured in the supernatant of stimulated cells, and the ELISpot assay where interferon γ is locally captured in microtiter plates. The disadvantage of these methods is that they do not allow a subclassification of stimulated cells, i.e., in CD4- and CD8-positive cells. The use of intracellular cytokine staining followed by flow cytometry overcomes this drawback and allows a complete sub-characterization of virus-specific T cells, but comes at the price of a longer and more difficult methodology. In contrast, MHC multimer staining is rapid and independent of stimulation but has the disadvantage that special MHC/peptide complexes have to be manufactured for each antigen and MHC allele so that this test is expensive and cumbersome, making it unfeasible for use in routine care [21].

There are two easy to apply assays which are commercially available for measuring the cellular response to CMV viremia but they do not directly determine the number of virus-specific T cells: QuantiFERON CMV, which is a whole blood interferon-gamma release assay based on ELISA technology [22] and T-Track CMV, which is an ELISpot assay [23]. Both assays have been used in initial diagnostic trials to determine diagnostic cutoff values [24, 25]. These assays are simple to use but both have the limitation that they only give a rough estimation of T cell activation. An analysis on the cellular level is not possible. For QuantiFERON CMV, it has been shown that it might provide false-negative results if compared with flow cytometry analysis [10]. And in a comparison between both tests, “T-Track CMV” performed better than “QuantiFERON CMV” [25]. To date, neither test has been investigated in children so it is therefore difficult to rate their diagnostic value for pediatric kidney recipients. Comparable assays are not manufactured for other viruses.

Cytomegalovirus-specific T cells

CMV infections and CMV reactivations belong to the most common viral complications after kidney transplantation and can lead to severe morbidity by generalized CMV disease and to impairment of graft function [1]. The risk assessment for CMV-associated complications is made according to the pre-transplant CMV serostatus of recipient and donor. For pediatric kidney transplantation, the international consensus guidelines recommend the use of antiviral prophylaxis with (val-)ganciclovir for 3–6 months in the case of a seropositive donor and/or seropositive recipient; in seropositive recipients, pre-emptive therapy is considered as an alternative [26], but this medication has severe side effects such as neutropenia and nephrotoxicity [27]. However, CMV serology and DNA load are insufficient to predict the individual course of CMV DNAemia and the risk of CMV-associated complications. CMV-specific T cells control virus replication and preliminary studies have already found that the risk of post-transplant CMV-induced disease correlated with the individual number of CMV-specific T cells. Reduced frequencies of CMV-specific T cells in transplant recipients are associated with increased incidence of infectious complications [14, 28–30]. It was proven that after adult kidney transplantation, symptomatic CMV reactivations are preceded by a decrease in CMV-specific CD4 T cells frequencies and an increase in
CMV load [30]. Gamadia et al. determined the kinetics and characteristics of CMV-specific T cells in the course of primary CMV infections in adult renal transplant recipients. In asymptomatic individuals, the CMV-specific CD4 T cells response preceded CMV-specific CD8 T cells response, whereas in symptomatic individuals, the CMV-specific effector memory CD4 T cell response was delayed and only detectable after antiviral therapy [31, 32]. The number of CMV-specific T cells before and after transplantation correlated with the risk of post-transplant CMV-associated events and DNAemia [33, 34]. This was also true for patients receiving anti-thymocyte globulin induction therapy [35]. Interestingly, in patients treated with the mammalian target of rapamycin (mTOR) inhibitor everolimus, the CMV-specific T cell response was more robust as compared with standard immunosuppression [36]. In immunocompetent individuals, CMV-specific T cells are induced at onset of primary infection and persist lifelong, whereas those without CMV infection do not show any specific cellular immunity. Usually, CMV-specific T cells correlate well with CMV serology [37], but in the case of unclear CMV-serostatus, analysis of CMV-specific T cells provides a reliable alternative to determine the pre-transplant CMV infection status, especially in patients with passive humoral immunity after infusions of plasma preparations [38], or in infants with passive maternal antibodies [39]. The pre-transplant absence of CMV-specific T cells in CMV-IgG-positive patients identifies CMV-naïve patients at risk of post-transplant CMV-associated complications. Recently, the reverse situation was also reported, meaning that some CMV-IgG-negative kidney recipients showed pre-transplant detection of CMV-specific T cells associated with post-transplant protection from CMV infection [8, 40, 41]. Accordingly, monitoring of CMV-specific T cells offers a superior, more reliable risk assessment of post-transplant CMV complications compared with CMV serostatus alone. In a first interventional trial using the QuantiFERON CMV assay, it was proven that CMV-specific cell-mediated immunity can be used to steer the length of antiviral therapy in the case of CMV viremia after solid organ transplantation [42].

Especially in pediatric kidney recipients, who have a significantly higher rate of CMV negativity at time of transplantation and thereby a higher risk of post-transplant primary CMV infection, pre- and post-transplant monitoring of CMV-specific T cells might become a diagnostic tool to optimize the post-transplant management of antiviral prophylaxis and therapy. However, pediatric data concerning CMV-specific T cell monitoring after solid organ transplantation are rare. Our own observational study of pediatric kidney recipients showed that symptomatic courses of CMV infections and reactivations were found in the case of low CMV-specific CD4 T cell levels, whereas children with high virus-specific CD4 T cells showed asymptomatic courses. Until now, pediatric data has only been available in abstract form. Analysis of CMV-specific CD4 T cells might help to identify patients at risk of symptomatic CMV infections/reactivations and to decide upon necessity for and duration of antiviral prophylaxis and therapy. Hence, pre- and post-transplant monitoring of CMV-specific CD4 T cells may personalize CMV management and avoid unnecessary antiviral medication in CMV-IgG-positive children with sufficient levels of CMV-specific T cells. Further studies guiding CMV prophylaxis and therapy in children using virus-specific T cells are eagerly awaited.

**Adenovirus-specific T cells**

ADV infections are not uncommon after pediatric kidney transplantation but seldom lead to clinical problems [43–46], whereas morbidity is much higher after stem cell transplantation [47]. There are only a few studies available concerning ADV-specific T cells after solid organ transplantation. The levels of ADV-specific T cells were investigated in adult renal transplant recipients and healthy individuals by cytokine flow cytometry [48]. In Philadelphia, Olive et al. analyzed the ADV-specific T cell response of healthy adults by ELISpot and flow cytometry [49]. Some data on ADV-specific T cells was generated by ELISpot in a small group of children after liver transplantation [50]. In one child with ADV pneumonia, ADV-specific T cells were measured after lung transplantation and the possibility of steering antiviral therapy using ADV-specific T cells is reported [11]. In our own cohort of 37 pediatric kidney recipients aged between 1 and 17 years (median 13 years), the pre-transplant prevalence of ADV-specific CD4 T cells was 76% (data not published) without any ADV-associated complications after kidney transplantation. In accordance with CMV-specific T cell data, ADV-specific T cells were permanently detectable after primary infection and fluctuated depending on the intensity of immunosuppression. Under the strengthened immunosuppression during the initial post-transplant period, we found a temporary decrease of virus-specific T cells. After reduction of the immunosuppressive therapy, virus-specific T cells began increasing again in our cohort of pediatric kidney recipients. Regarding high prevalence in childhood, ADV-specific T cells may serve as a suitable parameter to estimate the post-transplant intensity of immunosuppression and to steer the doses of the immunosuppressive medication, as is recently examined by our multicenter, randomized controlled trial (IVIST trial) [20]. Besides the use of ADV-specific T cells in our IVIST trial, no other clinical application for ADV-specific T cell monitoring after pediatric kidney transplantation has been published to date. This might be because of the very
BK polyomavirus-specific T cells

After kidney transplantation, primary BKPyV infections or reactivations can lead to BKPyV-associated nephropathy (BKPyV AN) with renal malfunction and risk of graft loss [5, 51–53]. In the absence of BKPyV-specific antiviral drugs, BKPyV-DNAemia-triggered reduction of maintenance immunosuppression is currently recommended in patients with BKPyV-DNAemia [5]. However, the pathophysiology of BKPyV AN is complex and the level of BKPyV-DNA in plasma alone is insufficient to estimate the risk of onset of BKPyV AN and to decide upon the necessity for therapeutic intervention [54]. It is known that BKPyV viremia after kidney transplantation does not result inevitably in BKPyVAN. Many kidney recipients show self-limiting BKPyV viremia without therapeutic interventions [53, 55, 56]. In these cases, pre-emptive reduction of immunosuppression is not only unnecessary but also associated with an increased risk of rejection.

In contrast to BKPyV antibodies, BKPyV-specific cellular immunity seems to play an important role in controlling viral replication. A few adult studies recently observed that an increase of BKPyV-specific T cells coincided with viral clearance in kidney transplant recipients [57, 58]. Accordingly, an insufficient level of BKPyV-specific T cells seems to be a key mechanism of BKPyV-associated complications after kidney transplantation. Ginevri et al. analyzed 13 pediatric kidney recipients with BKPyV-DNAemia and confirmed that a reduction of BKPyV-DNA in plasma is associated with an increase in BKPyV-specific T cells supporting the theory that the expansion of BKPyV-specific cellular immunity has a protective role [59]. Concerning BKPyV reactivations, Costa and colleagues observed episodes of BKPyV reactivation only in patients without a BKPyV-specific cellular immune response [19] and Schachtner et al. recently demonstrated that kidney transplant recipients with loss of BKPyV-specific T cells over the pre- to post-transplant period were at increased risk of BKPyV replication [18]. In 2011 and 2014, Schachtner et al. reported in a small study group of viremic patients that kidney recipients with self-limited BKPyV reactivation developed BKPyV-specific T cells without therapeutic intervention, whereas patients with BKPyVAN showed BKPyV-specific T cells only after successful treatment [55, 56]. Moreover, our own monocentric prospective, non-interventional study including 32 viremic children after kidney transplantation showed the following result: High levels of BKPyV-specific CD4 and/or CD8 T cells predicted asymptomatic BKPyV infections with self-limiting, short-term viremia (< 120 days), whereas lack or low levels of BKPyV-specific T cells were associated with long-term viremia and florid BKPyVAN [60]. Of note, the BKPyV-specific T cell level correlated with the subsequent duration of viremia but not with the BKPyV-DNA load in plasma, highlighting the additional benefit of BKPyV-specific T cells. The detection of BKPyV-specific CD4 T cells (≥ 0.5 cells/μL) and/or CD8 T cells (≥ 0.1 cells/μL) revealed a positive predictive value of 1.0 and a negative predictive value of 0.86 for self-limiting viremia. After minimization of immunosuppressive therapy and/or switch to mTOR inhibitors, BKPyV-specific CD4 T cells increased with subsequent decrease of plasma BKPyV-DNA [60].

These data highlight the predictive value of BKPyV-specific T cells after pediatric kidney transplantation to distinguish patients with self-limiting, short-term viremia from those with long-term viremia and need of therapeutic intervention. Serving as a prognostic marker, BKPyV-specific T cells may therefore identify patients at risk of BKPyVAN and thereby individualize therapeutic interventions [61].

Epstein-Barr virus-specific T cells

Primary EBV infections or reactivations after solid organ transplantation can lead to symptomatic EBV viremia and to the development of post-transplant lymphoproliferative disease (PTLD) [62]. It has already been shown that EBV-specific T cells can be detected in children after kidney and liver transplantation but results were not associated with clinical events in this trial [13]. In a small group of pediatric liver recipients, EBV-specific T cells were monitored during first post-transplant year by ELISpot including three patients with EBV reactivations. This prospective single center study observed an immediate decline of EBV-specific T cells after transplantation and an increase after reduction of immunosuppression [50]. In addition, EBV-specific T cells have been measured in children with PTLD after solid organ transplantation, seven of whom were kidney recipients [63]. They showed an increase during PTLD treatment and a rapid re-increase in the case of EBV viremia after PTLD and can therefore be used to estimate the individual prognosis. Unfortunately, no trials have been performed to date directing PTLD treatment based on EBV-specific T cells levels. In thoracic transplantation, it could also be demonstrated that the phenotype of EBV-specific T cells varies with the severity of infection [64]. Our own data concerning EBV-specific T cells after pediatric kidney transplantation, as yet only available in abstract form, have shown that high levels of EBV-specific CD4 T cells are associated with asymptomatic self-limiting EBV viremia, whereas lack or low levels of EBV-specific CD4 T cells are found in the case of symptomatic, long-term viremia.
**Therapy with virus-specific T cells**

The transfer of engineered virus-specific T cells has increasingly been used to treat life-threatening CMV [65], EBV [66], and ADV infections [67] after stem cell transplantation. The safety and efficacy of broad-spectrum T cells as treatment for ADV, EBV, CMV, and BKPyV infections after stem cell transplantation was published by Papadopoulou et al. [68]. However, data concerning therapy with virus-specific T cells after solid organ transplantation are rare. In 2016, Roemhild and Reinke summarized the data on virus-specific T cell transfer in solid organ transplantation, mainly concentrating on therapy with EBV-specific T cells in adults [69]. After solid organ transplantation, data on therapy with EBV-specific T cells are far more frequently published compared with data for CMV-specific T cells or other viruses. In children, there are only a few case reports and small case series on EBV-specific T cell therapy for treatment of EBV-associated PTLD after kidney and liver transplantation [70, 71]. However, not even as much as a case report has been published about adoptive T cell transfer in children after solid organ transplantation with viral diseases other than EBV-associated PTLD. As this method is expensive and associated with high risks for the recipient, future reports and studies are awaited, so that the clinical utility of treatment with virus-specific T cells can be assessed for children after solid organ transplantation. It can be speculated that therapy with virus-specific T cells will be limited to children with infections that are associated with a high risk of graft loss (i.e., BKPyVAN) or life-threatening disease (i.e., PTLD) and which are resistant to any other treatment.

**Steering of immunosuppressive therapy by virus-specific T cells**

Post-transplant monitoring of virus-specific T cells showed that levels of virus-specific T cells fluctuated depending on the intensity of immunosuppression. During the initial post-transplant period—at the time of very intensive immunosuppressive therapy—virus-specific T cells were decreased and showed increase after reduction of immunosuppressants [7]. Accordingly, it is hypothesized that virus-specific T cells represent not only virus specific but also general cellular immune defense and thereby correlate with the individual susceptibility to infections. Serving as a marker of overimmunosuppression, additional monitoring of virus-specific T cells might optimize steering of immunosuppressive therapy compared with blood level monitoring alone [7]. To our knowledge, our IVIST trial is the first study considering the benefit of additional steering of immunosuppressive drugs by virus-specific T cells. The study protocol of this investigator-initiated, multicenter, randomized controlled trial has been already published [20]. Sixty-four pediatric kidney recipients were randomized 4 weeks after transplantation either to a non-intervention group with classical trough level monitoring of immunosuppressants or to an intervention group with additional steering by virus-specific T cell levels against CMV, ADV, and herpes simplex virus (HSV). Regarding high prevalence in childhood (especially of ADV-specific T cells) and long-term persistency after primary infection, CMV-, ADV-, and HSV-specific T cells are suitable for post-transplant monitoring. Both groups received the same immunosuppressive regimen consisting of cyclosporine A and everolimus with the same target range of trough levels. The primary endpoint of the study is the glomerular filtration rate (GFR) years after transplantation. Secondary endpoints are the number and severity of infections and the exposure to immunosuppressive drugs. In terms of an effect-related drug monitoring, the study design aims to realize a personalization of immunosuppressive management after transplantation. The results of the trial are expected in 2020 and, hopefully then, the IVIST trial will answer the question of whether the new concept of steering immunosuppressive therapy by virus-specific T cell levels leads to optimization of post-transplant management.

**Conclusion**

New diagnostic strategies using markers of the individual cellular immune response such as virus-specific T cells seem to be promising in pediatric kidney transplantation to estimate the outcome of post-transplant viral infections and to decide on the necessity of antiviral medication and/or reduction of immunosuppressive therapy and thereby to avoid unnecessary therapeutic intervention. Analysis of virus-specific T cells may become an important step towards the introduction of precision medicine in pediatric kidney transplantation. The measurement of virus-specific T cells at time of onset of viremia, challenging whether a therapeutic intervention should be performed, could become a part of routine care. Prospective, interventional trials comparing standard of care with T cell-based steering of antiviral and immunosuppressive therapy in case of post-transplant viral infections are needed in order to confirm the usability of this strategy in viremic patients. Furthermore, if the strategy can be confirmed in prospective trials, virus-specific T cells might also be used as an additional routine tool to measure the intensity of immunosuppression after pediatric kidney transplantation in order to avoid overimmunosuppression.
Funding Information  Open Access funding provided by Projekt DEAL.

Compliance with ethical standards

Conflict of interest  The authors declare that they have no conflicts of interest.

Abbreviations  ADV, Adenovirus; BKPyV, BK polyomavirus; BKPyVAN, BK polyomavirus-associated nephropathy; CMV, cytomegalovirus; EBV, Epstein-Barr virus; ELISA, enzyme-linked immunosorbent assay; ELISpot, enzyme-linked immunospot; FACS, fluorescence-activated cell sorting; GFR, glomerular filtration rate; HSV, herpes simplex virus; MHIC, major histocompatibility complex; mTOR, mammalian target of rapamycin; PCR, polymerase chain reaction; PTLD, post-transplant lymphoproliferative disease

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Hocker B, Zenecke S, Krupka K, Fichtner A, Pape L, Dello Strologo L, Guizzo I, Topaloglu R, Kranz B, Konig J, Bald M, Webb NJ, Noyan A, Dursun H, Marks S, Yalcinkaya F, Thiel F, Billing H, Pohl M, Fehrenbach H, Bruckner T, Tonshoff B (2016) Cytomegalovirus infection in pediatric renal transplantation and the impact of chemoprophylaxis with (val-)ganciclovir. Transplantation 100:862–870
2. Höcker B, Schneele L, Murer L, Carraro A, Pape L, Kranz B, Oh J, Zingibl M, Dello Strologo L, Büscher A, Weber LT, Awan A, Pohl M, Bald M, Printza N, Rusai K, Peruzzi L, Topaloglu R, Fichtner A, Krupka K, Köster L, Bruckner T, Schützler P, Hirsch HH, Tonshoff B (2019) Epidemiology of and risk factors for BK polyomavirus replication and nephropathy in pediatric renal transplant recipients: an international certain registry study. Transplantation 103:1224–1233
3. Laurent A, Küch A, Roy P, Lina B, Kassai B, Bacchetta J, Cochot P (2018) Pediatric renal transplantation: a retrospective single-center study on epidemiology and morbidity due to EBV. Pediatr Transplant 22:e13151
4. Preiksaitis JK, Brennan DC, Fishman J, Allen U (2005) Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 5:218–227
5. Hirsch HH, Randhawa PS, AST Infectious Diseases Community of Practice (2019) BK polyomavirus in solid organ transplantation—guidelines from the american society of transplantation infectious diseases community of practice. Clin Transpl 33:e13528
6. Allen UD, Preiksaitis JK, AST Infectious Diseases Community of Practice (2019) Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: guidelines from the american society of transplantation infectious diseases community of practice. Clin Transpl 33:e13652
7. Sester M, Leboeuf C, Schmidt T, Hirsch HH (2016) The “ABC” of virus-specific T cell immunity in solid organ transplantation. Am J Transplant 16:1697–1706
8. Schachtner T, Stein M, Reineke P (2017) CMV-specific T cell monitoring offers superior risk stratification of CMV-seronegative kidney transplant recipients of a CMV-seropositive donor. Transplantation 101:e315–e325
9. De Gracia-Guido MDC, Ruiz-Fuentes MDC, Galindo-Sacristán P, Osorio-Moratalla JM, Ruiz-Fuentes N, Rodríguez Granger J, Osuna-Ortega A (2018) Cytomegalovirus infection monitoring based on interferon gamma release assay in kidney transplantation. Transplant Proc 50:578–580
10. Gabanti E, Lillieri D, Scaramuzza L, Zelini P, Rampino T, Gerna G (2018) Comparison of the T-cell response to human cytomegalovirus (HCMV) as detected by cytokine flow cytometry and QuantiFERON-CMV assay in HCMV-seropositive kidney transplant recipients. New Microbiol 41:195–202
11. Schulzke-Flore RE, Tischer S, Schwerk N, Heim A, Eiz-Vesper B, Maeker-Kolhoff B (2016) Monitoring of adenovirus (ADV)-specific T cells in a boy with ADV pneumonia and disseminated disease after lung transplantation. Transpl Infect Dis 18:756–760
12. Lee SM, Kim YJ, Yoo KH, Sung KW, Koo HH, Kang ES (2017) Clinical usefulness of monitoring cytomegalovirus-specific immunity by quantiferon-CMV in pediatric allogeneic hematopoietic stem cell transplantation recipients. Ann Lab Med 37:277–281
13. Falco DA, Nepomuceno RR, Krams SM, Lee PP, Davis MM, Salvatiera O, Alexander SR, Esquivel CO, Cox KL, Frankel LR, Martínez OM (2002) Identification of Epstein-Barr virus-specific CD8+ T lymphocytes in the circulation of pediatric transplant recipients. Transplantation 74:501–510
14. Tu W, Potena L, Stepick-Biek P, Liu L, Dionis KY, Luikart H, Fearon WF, Holmes TH, Chin C, Cooke JP, Valentine HA, Mocarski ES, Lewis DB (2006) T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease. Circulation 114:1608–1615
15. Amyes E, Hatton C, Montamat-Sicotte D, Gudgeon N, Rickinson AB, McMichael AJ, Callan MF (2003) Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection. J Exp Med 198:903–911
16. Comoli P, Azzi A, Maccario R, Basso S, Botti G, Basile G, Fontana I, Labirio M, Corneta A, Poli F, Perfumo F, Localleti F, Ginevri F (2004) Polyomavirus BK-specific immunity after kidney transplantation. Transplantation 78:1229–1232
17. Leboeuf C, Wilk S, Achermann R, Binet I, Golshayan D, Hadaya K, Hirzel C, Hoffmann M, Huynd-Do U, Koller MT, Manuel O, Mueller NJ, Mueller TF, Schaub S, van Delden C, Weissbach FH, Hirsch HH, Swiss Transplant Cohort Study (2017) BK polyomavirus-specific 9mer CD8 T cell responses correlate with clearance of BK viremia in kidney transplant recipients: first report from the swiss transplant cohort study. Am J Transplant 17:2591–2600
18. Schachtner T, Stein M, Babel N, Reineke P (2015) The loss of BKV-specific immunity from pretransplantation to posttransplantation identifies kidney transplant recipients at increased risk of BKV replication. Am J Transplant 15:2159–2169
19. Costa C, Mantovani S, Piceghello A, Di Nauta A, Sinesi F, Sidoti F, Messina M, Cavallo R (2014) Evaluation of polyomavirus BK cellular immune response by an ELISpot assay and relation to viral replication in kidney transplant recipients. New Microbiol 37:219–223
20. Ahenstiel-Grunow T, Koch A, Grosshennig A, Fromke C, Sester M, Sester U, Schroder C, Pape L (2014) A multicenter, randomized, open-labeled study to steer immunosuppressive and antiviral
therapy by measurement of virus (CMV, ADV, HSV)-specific T cells in addition to determination of trough levels of immunosuppressants in pediatric kidney allograft recipients (IVIST01-trial): study protocol for a randomized controlled trial. Trials 15:324.

21. Calarota SA, Aberle JH, Puchhammer-Stockl E, Baldanti F (2015) Approaches for monitoring of non-virus-specific and virus-specific T-cell response in solid organ transplantation and their clinical applications. J Clin Virol 70:109–119.

22. Lochmanova A, Lochman I, Tomaskova H, Marsalkova P, Raszka J, Mrazek J, Dedochova J, Martinek A, Brozmannova H, Grundmann M (2010) Quantiferon-CMV test in prediction of cytomegalovirus infection after kidney transplantation. Transplant Proc 42:3574–3577.

23. Banas B, Boger CA, Luckhoff G, Kruger B, Barabas S, Batzila J, Schemmer M, Kostler J, Bendfeldt H, Rasce A, Wagner R, Deml L, Leicht J, Kramer BK (2017) Validation of T-track(R) CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients. BMC Immunol 18:15.

24. Banas B, Steubl D, Renders L, Chittka D, Banas MC, Wekerle T, Koch M, Witzke O, Muhlfeld A, Sonnemer C, Habicht A, Hugo C, Hunig T, Lindemann M, Schmidt T, Rasce A, Barabas S, Deml L, Wagner R, Kramer BK, Kruger B (2018) Clinical validation of a novel enzyme-linked immunosorbent spot assay-based in vitro diagnostic assay to monitor cytomegalovirus-specific cell-mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study. Transpl Int 31:436–450.

25. Gliga S, Korth J, Krawczyk A, Wilde B, Horn PA, Witzke O, Lindemann M, Fiedler M (2018) T-track-CMV and Quantiferon-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients. J Clin Virol 105:91–96.

26. Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L, Humar A, The Transplantation Society International CMV Consensus Group (2018) The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 102:900–931.

27. Marshall BC, Koch WC (2009) Antivirals for cytomegalovirus infection in neonates and infants: focus on pharmacokinetics, formulations, dosing, and adverse events. Paediatr Drugs 11:309–321.

28. Sester M, Sester U, Gartner B, Heine G, Girndt M, Mueller-Lantzsch N, Meyerhans A, Kohler H (2001) Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 71:1287–1294.

29. Sester U, Gartner BC, Wilkens H, Schwaab B, Wossner R, Kindermann I, Girndt M, Meyerhans A, Mueller-Lantzsch N, Schafer HS, Sybrecht GW, Kohler H, Sester M (2005) Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant 5:1483–1489.

30. Radha R, Jordan S, Puliyanada D, Bunnaprastid S, Petrosyan A, Ament N, Toyoda M (2005) Cellular immune responses to cytomegalovirus in renal transplant recipients. Am J Transplant 5:110–117.

31. Gamadia LE, Remmerswaal EB, Weel JF, Bemelman F, van Lier RA, Ten Berge IJ (2003) Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood 101:2686–2692.

32. Gamadia LE, Rentenaar RJ, van Lier RA, ten Berge IJ (2004) Properties of CD4(+) T cells in human cytomegalovirus infection. Hum Immunol 65:486–492.

33. Molina-Ortega A, Martin-Gandul C, Mena-Romo JD, Rodriguez-Hernandez MJ, Suner M, Bernal C, Sanchez M, Sanchez-Cespedes J, Perez Romero P, Cordero E (2019) Impact of pretransplant CMV-specific T-cell immune response in the control of CMV infection after solid organ transplantation: a prospective cohort study. Clin Microbiol Infect 25:753–758.

34. Fernandez-Ruiz M, Gimenez E, Vinuesa V, Ruiz-Merlo T, Parra P, Amat P, Montejo M, Paez-Vega A, Cantisan S, Torre-Cisneros J, Fortun J, Andres A, San Juan R, Lopez-Medrano F, Navarro D, Aguado JM, & Group for Study of Infection in Transplantation of the Spanish Society of Infectious Diseases and Clinical Microbiology (GESITRA-SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI) (2019) Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment. Clin Microbiol Infect 25:381.e1–381.e10.

35. Martin-Gandul C, Perez-Romero P, Mena-Romo D, Molina-Ortega A, Gonzalez-Roncero FM, Suner M, Bernal G, Cordero E, Spanish Network for Research for Resistant T cells are Detectable (REIPI) (2018) Kinetic of the CMV-specific T-cell immune response and CMV infection in CMV-seropositive kidney transplant recipients receiving rabbit anti-thymocyte globulin induction therapy: a pilot study. Transpl Infect Dis 20:1228–33.

36. Havenith SH, Yong SL, van Donselaar-van der Pant KA, van Lier RA, ten Berge IJ, Bemelman FJ (2015) Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients. Transplantation 95:184–191.

37. Sester M, Gartner BC, Sester U, Girndt M, Mueller-Lantzsch N, Kohler H (2003) Is the cytomegalovirus serologic status always accurate? A comparative analysis of humoral and cellular immunity. Transplantation 102:1229–1230.

38. Schmidt T, Ritter M, Dirks J, Gartner BC, Sester U, Sester M (2012) Cytomegalovirus-specific T-cell immunity to assign the infection status in individuals with passive immunity: a proof of principle. J Clin Virol 54:272–275.

39. Ritter M, Schmidt T, Dirks J, Hennes P, Juhasz-Boss I, Solomayer EF, Gartner L, Gartner B, Rohrer T, Sester U, Sester M (2013) Cytomegalovirus-specific T cells are detectable already in early childhood and allow assignment of the infection status in children with passive maternal antibodies. Eur J Immunol 43:1099–1108.

40. Litjens NHR, Huang L, Dedeoglu B, Meijers RWJ, Kweekelboom J, Betjes MGH (2017) Protective cytomegalovirus (CMV)-specific T-cell immunity is frequent in kidney transplant patients without serum anti-CMV antibodies. Front Immunol 8:1137.

41. Lucia M, Crespo E, Mellili E, Cruzado JM, Luque S, Llado I, Niubo J, Torras J, Fernandez N, Grinyo JM, Bestard O (2014) Preformed frequencies of cytomegalovirus (CMV)-specific memory T and B cells identify protected CMV-sensitized individuals among seronegative kidney transplant recipients. Clin Infect Dis 59:1537–1545.

42. Kumar D, Mian M, Singer L, Humar A (2017) An interventional study using cell-mediated immunity to personalize therapy for cytomegalovirus infection after transplantation. Am J Transplant 17:2468–2473.

43. Lee B, Park E, Ha J, Ha IS, Il Cheong H, Kang HG (2018) Disseminated adenovirus infection in a 10-year-old renal allograft recipient. Kidney Res Clin Pract 37:414–417.

44. Keswani M, Moudgil A (2007) Adenovirus-associated hemorrhagic cystitis in a pediatric renal transplant recipient. Pediatr Transplant 11:568–571.

45. Mehta V, Chou PC, Picken MM (2015) Adenovirus disease in six small bowel, kidney and heart transplant recipients: pathology and clinical outcome. Virchows Arch 467:603–608.

46. Engen RM, Huang ML, Park GE, Smith JM, Limaye AP (2018) Prospective assessment of adenovirus infection in pediatric kidney transplant recipients. Transplantation 102:1165–1171.

47. Sedlacek P, Pettersson T, Robin M, Sivaprakasam P, Vainorius E, Brundage T, Chandak A, Moazzafari E, Nichols G, Voigt S (2019) Incidence of adenovirus infection in hematopoietic stem cell
transplantation recipients: findings from the AdVance study. Biol Blood Marrow Transplant 25: 810–818
48. Sester M, Sester U, Alarcon Salvador S, Heine G, Lipfert S, Gimdt M, Gartner B, Kohler H (2002) Age-related decrease in adenovirus-specific T cell responses. J Infect Dis 185: 1379–1387

49. Olive M, Eisenlohr LC, Flommen P (2001) Quantitative analysis of adenovirus-specific CD4+ T-cell responses from healthy adults. Viral Immunol 14:403–413

50. Arasaratnam RJ, Tzannou I, Gray T, Aguayo-Hinckel PI, Kuvalakar M, Naik S, Gaikwad A, Liu H, Miloh T, Vera JF, Himes RW, Munoz FM, Leen AM (2018) Dynamics of virus-specific T cell immunity in pediatric liver transplant recipients. Am J Transplant 18:2238–2249

51. Ramos E, Drachenberg CB, Wali R, Hirsch HH (2009) The decade of polyomavirus BK-associated nephropathy: state of affairs. Transplantation 87:621–630

52. Hirsch HH, Knowles W, Dickenmann M, Passweg J, Klimkait T, Mihatsch MJ, Steiger J (2002) Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 347:488–496

53. Elfdawy N, Flechner SM, Schold JD, Srinivas TR, Poggio E, Fatica R, Avery R, Mossad SB (2014) Transient versus persistent BK viremia and long-term outcomes after kidney and kidney-pancreas transplantation. Clin J Am Soc Nephrol 9:553–561

54. Almeras C, Fouloungne V, Garrigue V, Szwarz I, Vetromile F, Segondy M, Mourad G (2008) Does reduction in immunosuppression in viremic patients prevent BK virus nephropathy in de novo renal transplant recipients? A prospective study. Transplantation 85:1099–1104

55. Schachtner T, Stein M, Sefrin A, Babel N, Reinke P (2014) Inflammatory activation and recovering BKV-specific immunity correlate with self-limited BKV replication after renal transplantation. Transpl Int 27:290–301

56. Schachtner T, Muller K, Stein M, Diezemann C, Sefrin A, Babel N, Reinke P (2011) BK virus-specific immunity kinetics: a predictor of recovery from polyomavirus BK-associated nephropathy. Am J Transplant 11:2443–2452

57. Binggeli S, Egli A, Schaub S, Binet I, Mayr M, Steiger J, Hirsch HH (2007) Polyomavirus BK-specific cellular immune response to VP1 and large T-antigen in kidney transplant recipients. Am J Transplant 7:1131–1139

58. Prosser SE, Orentas RJ, Jurgens L, Cohen EP, Hartharan S (2008) Recovery of BK virus large T-antigen-specific cellular immune response correlates with resolution of BK virus nephritis. Transplantation 85:185–192

59. Ginevri F, Azzi A, Hirsch HH, Basso S, Fontana I, Cioni M, Bodaghi S, Salotti V, Riniari A, Botti G, Perfumo F, Locatelli F, Comoli P (2007) Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant 7:2727–2735

60. Ahlenstiel-Grunow T, Sester M, Sester U, Hirsch HH, Pape L (2020) Polyomavirus-specific T cells as a diagnostic and prognostic marker for BK polyomavirus infections after pediatric kidney transplantation. Transplantation https://doi.org/10.1097/TP.0000000000003133

61. Ahlenstiel-Grunow T, Pape L (2020) Diagnostics, treatment, and immune response in BK polyomavirus infection after pediatric kidney transplantation. Pediatr Nephrol 35:375–382

62. Kanzelmeyer NK, Maercker-Kollhoff B, Zierhut H, Lerch C, Verboom M, Haffner D, Pape L (2018) Graft outcomes following diagnosis of post-transplant lymphoproliferative disease in pediatric kidney recipients: a retrospective study. Transpl Int 31:367–376

63. Wilsdorf N, Eiz-Vesper B, Henke-Gendo C, Diestelhorst J, Osschies I, Hussein K, Pape L, Baumann U, Tonshoff B, Pohl M, Hocker B, Wingen AM, Klappler W, Kreipe H, Schulz TF, Klein C, Maercker-Kollhoff B (2013) EBV-specific T-cell immunity in pediatric solid organ graft recipients with posttransplantation lymphoproliferative disease. Transplantation 95:247–255

64. Macedo C, Webber SA, Donnenberg AD, Popescu I, Hua Y, Green M, Rowe D, Smith L, Brooks MM, Metes D (2011) EBV-specific CD8+ T cells from asymptomatic pediatric thoracic transplant patients carrying chronic high EBV loads display contrasting features: activated phenotype and exhausted function. J Immunol 186:5854–5862

65. Pei XY, Zhao XY, Chang YJ, Liu J, Xu LP, Wang Y, Zhang XH, Han W, Chen YH, Huang XF (2017) Cytomegalovirus-specific T-cell transfer for refractory cytomegalovirus infection after haploidentical stem cell transplantation: the quantitative and qualitative immune recovery for cytomegalovirus. J Infect Dis 216:945–956

66. Icheva V, Kayser S, Wolff D, Tuve S, Kyzirakos C, Bethge W, Greil J, Albert MH, Schwinger W, Nathrath M, Schumann M, Stevanovic S, Handgretinger R, Lang P, Feuchtinger T (2013) Adoptive transfer of Epstein-Barr virus (EBV) nuclear antigen 1-specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J Clin Oncol 31:39–48

67. Ip W, Silva JMF, Gaspar H, Mitra A, Patel S, Rao K, Chiesa R, Amrolia P, Gilmour K, Ahsan G, Slatter M, Gennery AR, Wynn RF, Veys P, Qasim W (2018) Multicenter phase 1/2 application of adenovirus-specific T cells in high-risk pediatric patients after allogeneic stem cell transplantation. Cytotherapy 20:830–838

68. Papadopoulos A, Gerdemann U, Katari UL, Tzannou I, Liu H, Martinez C, Leung K, Carrum G, Gee AP, Vera JF, Kranze RA, Brenner MK, Rooney CM, Heslop HE, Leen AM (2014) Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med 6:242ra83

69. Roemhild A, Reinke P (2016) Virus-specific T-cell therapy in solid organ transplantation. Transplant Int 29:515–526

70. Chiofu PK, Beath SV, Wilke GM, Vickers MA, Morland B, Gupta GL (2018) Cytotoxic T-lymphocyte therapy for post-transplant lymphoproliferative disorder after solid organ transplantation in children. Pediatr Transplant 22:e13133

71. Comoli P, Maccario R, Locatelli F, Valente U, Basso S, Garaventa A, Toma P, Botti G, Melioli G, Baldanti F, Nocera A, Perfumo F, Ginevri F (2005) Treatment of EBV-related post-replant lymphoproliferative disease with a tailored regimen including EBV-specific T cells. Am J Transplant 5:1415–1422

Publisher’s note Springer Nature remains neutral with regard to jurisdic- tional claims in published maps and institutional affiliations.